A5055137470- Brain Metastases and Treatment
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- BRCA gene mutations in cancer
- Male Breast Health Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Radiopharmaceutical Chemistry and Applications
- Cancer and Skin Lesions
- Cancer Genomics and Diagnostics
- Breast Lesions and Carcinomas
- Cancer Risks and Factors
- Multiple and Secondary Primary Cancers
- Estrogen and related hormone effects
- Global Cancer Incidence and Screening
- Glioma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Ferrocene Chemistry and Applications
- Ethics in Clinical Research
- DNA and Nucleic Acid Chemistry
- Intellectual Property Rights and Media
- Monoclonal and Polyclonal Antibodies Research
- Cancer Diagnosis and Treatment
Dana-Farber Cancer Institute
2018-2025
Harvard University
2018-2025
Dana-Farber Brigham Cancer Center
2020-2025
Brigham and Women's Hospital
2021-2025
Broad Institute
2024
Yale Cancer Center
2024
Baylor College of Medicine
2024
Cancer Institute (WIA)
2024
Denali Therapeutics (United States)
2023
Olema Pharmaceuticals (United States)
2023
Given the clinical relevance of ESR1 mutations as potential drivers resistance to endocrine therapy, this study used sensitive detection methods determine frequency in primary and metastatic breast cancer, cell-free DNA (cfDNA).Six (K303R, S463P, Y537C, Y537N, Y537S, D538G) were assessed by digital droplet PCR (ddPCR), with lower limits 0.05% 0.16%, tumors (n = 43), bone 12) brain metastases 38), cfDNA 29). Correlations between lesions single (1 patient) or serial blood draws (4 patients)...
Patients with breast cancer (BrCa) brain metastases (BrM) have limited therapeutic options. A better understanding of molecular alterations acquired in BrM could identify clinically actionable metastatic dependencies.
Breast cancer brain metastases (BrMs) are defined by complex adaptations to both adjuvant treatment regimens and the microenvironment. Consequences of these alterations remain poorly understood, as does their potential for clinical targeting. We utilized genome-wide molecular profiling identify therapeutic targets acquired in metastatic disease.Gene expression 21 patient-matched primary breast tumors associated was performed TrueSeq RNA-sequencing determine clinically actionable BrM target...
Central nervous system (CNS) metastases are associated with poor prognosis in patients metastatic breast cancer (MBC). In this retrospective study, we investigated the activity of sacituzumab govitecan (SG) 33 HER2-negative MBC and CNS metastases, including active, stable/treated, leptomeningeal disease (LMD). SG demonstrated a modest objective response rate 4/30 (13%) median CNS-progression-free survival 2.9 months (95%CI:2.0-4.3) heavily pretreated population.
Distinguishing between osteomyelitis and neuropathic osteoarthropathy of the foot frequently presents a clinical radiologic challenge in patients with diabetes. Magnetic resonance (MR) imaging was performed 26 diabetic to observe changes signal intensity complicated foot. In every patient (n = 13), abnormalities were seen within bone marrow (low on T1-weighted images high T2-weighted 12 cases). Most these had cortical lesions 9) or associated soft-tissue infection 12). Normal observed three...
Brain metastasis (BM) in patients with breast cancer is a catastrophic event that results poor prognosis. Identification of prognostic factors associated brain metastases (BCBM) could help to identify at risk. The aim this study was assess clinical characteristics, factors, and survival BCBM who had craniotomy resection series treated modern multimodality therapy. We analyzed 42 underwent resection. Patients were diagnosed between April 1994 May 2010. Cox proportional hazards regression...
Abstract To evaluate the role of chemotherapy in stage IA triple-negative breast cancer, we conducted a retrospective population-based study including 8601 patients. The use significantly increased from 2010 to 2019 patients with T1b and T1c tumors ( p = 0.001 < 0.001, respectively). Receipt was associated improved cancer-specific survival (BCSS, adjusted hazard ratio 0.70; 0.006), particularly (5-year BCSS 94.5% vs. 91.2%).
Abstract Background We aimed to examine the safety and efficacy of bevacizumab carboplatin in patients with breast cancer brain metastases. Methods enrolled > 1 measurable new or progressive metastasis. Patients received 15 mg/kg intravenously (IV) on cycle day IV AUC = 5 8. HER2-positive disease also trastuzumab. In subsequent cycles, all drugs were administered each cycle. Contrast-enhanced MRI was performed at baseline, 24–96 h after first dose (day + 1), every 2 cycles. The primary...
Brain metastases are frequent in HER2-positive breast cancer. ONT-380 (tucatinib) is a potent selective inhibitor of HER2 with intracranial activity preclinical models.This was phase I study tucatinib trastuzumab, without chemotherapy, patients progressive, measurable brain metastases. The tested two schedules tucatinib: cohort A twice daily and B once daily. primary objective determination the maximum tolerated dose (MTD). Secondary end points included response (intracranial extracranial)...
In women with hormone receptor-positive (HR+) breast cancer, the risk of distant recurrence and death persists for at least 20 years from diagnosis. The late mortality in men HR+ cancer has not been reported.
Abstract BACKGROUND Historic data suggest that incidence of brain metastasis (BM) is relatively distributed over time in HER2-positive (HER2+) breast cancer (BC), occurs early triple negative BC (TNBC), and late hormone receptor-positive (HR+) metastatic (mBC). However, the timing BM relative to line therapy has not been well described. We describe prevalence per cumulative a large real-world cohort patients (pts) with mBC, by subtype therapy. METHODS This analysis used from longitudinal US...